Q: What is Evusheld used for?

Evusheld is used to treat COVID-19 pre-exposure prophylaxis.

Q: How does Evusheld work?

Mechanism of Action Evusheld consists of two long-acting monoclonal antibodies, tixagevimab and cilgavimab. These are proteins designed in a laboratory to mimic the immune system's ability to fight off harmful pathogens like viruses. The medication works through the following process: Targeting the Spike Protein: The antibodies specifically target the spike protein on the surface of the SARS-CoV-2 virus, which is the virus that causes COVID-19. Blocking Viral Entry: By binding to different, non-overlapping sites on the spike protein, the antibodies prevent the virus from attaching to human cells. This blocks the virus from entering the cells and replicating. Long-Lasting Protection: These antibodies have been modified to remain in the body for an extended period. This modification allows the medication to provide protection for several months after the initial administration. Unlike a vaccine, which teaches the immune system to create its own antibodies, Evusheld provides ready-made antibodies directly to the body to help prevent infection before exposure occurs. However, the effectiveness of these antibodies can change as the virus evolves into new variants.

Q: What are the active ingredients in Evusheld?

The active ingredients in Evusheld are Tixagevimab and Cilgavimab .

Q: What are the side effects of Evusheld?

Common side effects of Evusheld may include: Headache Fatigue Cough Always consult with a healthcare professional about potential side effects.

Q: What is the dosage of Evusheld and how do I take it?

Administration Evusheld is given as two separate, consecutive injections into the muscle. These injections are typically administered in the buttocks. A healthcare provider must give these injections in a medical setting where they can monitor you for any immediate side effects or allergic reactions. Monitoring After receiving the injections, you will be required to stay at the healthcare facility for a period of time, usually at least one hour. This allows medical staff to observe you and provide immediate care if you experience a reaction to the medication. Frequency When authorized for use, this medication was generally administered every six months. However, the FDA has currently withdrawn the authorization for Evusheld in the United States because it is unlikely to be effective against certain circulating variants of the virus that causes COVID-19.

Q: Is Evusheld safe during pregnancy and breastfeeding?

Pregnancy There are no clinical studies or data available regarding the use of Evusheld in pregnant individuals. It is unknown if the medication increases the risk of birth defects, miscarriage, or other adverse outcomes for the mother or the fetus. Because Evusheld is composed of monoclonal antibodies, it is expected that the medication can cross the placenta and be transferred to the developing fetus. Breastfeeding It is not known whether the components of Evusheld pass into human breast milk. There is also no information available on how the medication might affect a nursing infant or the production of breast milk. If you are breastfeeding, you should consult with your healthcare provider to discuss the potential risks and benefits of receiving this treatment. Consult Your Healthcare Provider If you are pregnant, planning to become pregnant, or are breastfeeding, it is important to talk to your doctor. They can help determine if the potential benefits of the medication outweigh the unknown risks based on your individual health needs and the risk of COVID-19 exposure.

Q: What is the FDA approval status of Evusheld?

Current Authorization Status As of January 26, 2023, Evusheld is not currently authorized for emergency use in the United States. The U.S. Food and Drug Administration (FDA) removed the authorization because the medication is unlikely to be effective against the SARS-CoV-2 variants that are currently most common in the country. Original Emergency Use Authorization The FDA originally issued an Emergency Use Authorization (EUA) for Evusheld in December 2021. It was authorized for pre-exposure prophylaxis (prevention) of COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) who met specific criteria: Individuals with moderate to severe immune system impairment who might not have an adequate immune response to COVID-19 vaccination. Individuals for whom COVID-19 vaccination is not recommended due to a history of severe adverse reactions to the vaccine or its components. Important Regulatory Limitations Evusheld was never FDA-approved for any indication; it was only available under an EUA. It was not authorized for the treatment of COVID-19 or for use as a preventative measure after a person had already been exposed to the virus. The FDA emphasized that Evusheld is not a substitute for vaccination in people for whom COVID-19 vaccination is recommended. The FDA continues to monitor the situation and may re-authorize the use of Evusheld if the prevalence of variants susceptible to the drug increases in the future. Healthcare facilities have been advised to retain their stock of the medication in case it becomes effective against future variants.

Question 1

What is Evusheld?

Accepted Answer

Evusheld is a medication composed of two monoclonal antibodies, tixagevimab and cilgavimab. These antibodies are laboratory-made proteins designed to mimic the immune system's natural ability to recognize and neutralize the SARS-CoV-2 virus.

By binding to the spike protein of the virus, the medication helps block the virus from entering and infecting healthy cells. This therapy provides a way to bolster the body's defenses against the virus that causes COVID-19.

Question 2

What is Evusheld used for?

Accepted Answer

Evusheld is used to treat COVID-19 pre-exposure prophylaxis.

Question 3

How does Evusheld work?

Accepted Answer

Mechanism of Action

Evusheld consists of two long-acting monoclonal antibodies, tixagevimab and cilgavimab. These are proteins designed in a laboratory to mimic the immune system's ability to fight off harmful pathogens like viruses.

The medication works through the following process:

Targeting the Spike Protein: The antibodies specifically target the spike protein on the surface of the SARS-CoV-2 virus, which is the virus that causes COVID-19.
Blocking Viral Entry: By binding to different, non-overlapping sites on the spike protein, the antibodies prevent the virus from attaching to human cells. This blocks the virus from entering the cells and replicating.
Long-Lasting Protection: These antibodies have been modified to remain in the body for an extended period. This modification allows the medication to provide protection for several months after the initial administration.

Unlike a vaccine, which teaches the immune system to create its own antibodies, Evusheld provides ready-made antibodies directly to the body to help prevent infection before exposure occurs. However, the effectiveness of these antibodies can change as the virus evolves into new variants.

Question 4

What are the active ingredients in Evusheld?

Accepted Answer

The active ingredients in Evusheld are Tixagevimab and Cilgavimab.

Question 5

What are the side effects of Evusheld?

Accepted Answer

Common side effects of Evusheld may include:

Headache
Fatigue
Cough

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Evusheld?

Accepted Answer

Evusheld belongs to the monoclonal antibody combination drug class.

Question 7

What is the dosage of Evusheld and how do I take it?

Accepted Answer

Administration

Evusheld is given as two separate, consecutive injections into the muscle. These injections are typically administered in the buttocks. A healthcare provider must give these injections in a medical setting where they can monitor you for any immediate side effects or allergic reactions.

Monitoring

After receiving the injections, you will be required to stay at the healthcare facility for a period of time, usually at least one hour. This allows medical staff to observe you and provide immediate care if you experience a reaction to the medication.

Frequency

When authorized for use, this medication was generally administered every six months. However, the FDA has currently withdrawn the authorization for Evusheld in the United States because it is unlikely to be effective against certain circulating variants of the virus that causes COVID-19.

Question 8

Is Evusheld safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

There are no clinical studies or data available regarding the use of Evusheld in pregnant individuals. It is unknown if the medication increases the risk of birth defects, miscarriage, or other adverse outcomes for the mother or the fetus. Because Evusheld is composed of monoclonal antibodies, it is expected that the medication can cross the placenta and be transferred to the developing fetus.

Breastfeeding

It is not known whether the components of Evusheld pass into human breast milk. There is also no information available on how the medication might affect a nursing infant or the production of breast milk. If you are breastfeeding, you should consult with your healthcare provider to discuss the potential risks and benefits of receiving this treatment.

Consult Your Healthcare Provider

If you are pregnant, planning to become pregnant, or are breastfeeding, it is important to talk to your doctor. They can help determine if the potential benefits of the medication outweigh the unknown risks based on your individual health needs and the risk of COVID-19 exposure.

Question 9

What forms and strengths does Evusheld come in?

Accepted Answer

Evusheld is provided as a co-packaged product containing two separate monoclonal antibody medications. It is available in the following form:

Injectable solution: Two separate vials containing sterile, preservative-free liquid for intramuscular administration.

The medication is administered by a healthcare provider as two separate, consecutive injections into the muscle, usually the buttocks.

Question 10

What is the FDA approval status of Evusheld?

Accepted Answer

Current Authorization Status

As of January 26, 2023, Evusheld is not currently authorized for emergency use in the United States. The U.S. Food and Drug Administration (FDA) removed the authorization because the medication is unlikely to be effective against the SARS-CoV-2 variants that are currently most common in the country.

Original Emergency Use Authorization

The FDA originally issued an Emergency Use Authorization (EUA) for Evusheld in December 2021. It was authorized for pre-exposure prophylaxis (prevention) of COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) who met specific criteria:

Individuals with moderate to severe immune system impairment who might not have an adequate immune response to COVID-19 vaccination.
Individuals for whom COVID-19 vaccination is not recommended due to a history of severe adverse reactions to the vaccine or its components.

Important Regulatory Limitations

Evusheld was never FDA-approved for any indication; it was only available under an EUA. It was not authorized for the treatment of COVID-19 or for use as a preventative measure after a person had already been exposed to the virus. The FDA emphasized that Evusheld is not a substitute for vaccination in people for whom COVID-19 vaccination is recommended.

The FDA continues to monitor the situation and may re-authorize the use of Evusheld if the prevalence of variants susceptible to the drug increases in the future. Healthcare facilities have been advised to retain their stock of the medication in case it becomes effective against future variants.

Question 11

What should I know about Evusheld and covid?

Accepted Answer

Prevention of COVID-19

Evusheld is a combination of two monoclonal antibodies, tixagevimab and cilgavimab, designed to prevent COVID-19. It was authorized for use in individuals who are unlikely to have an adequate immune response to COVID-19 vaccination or those for whom vaccination is not recommended due to a history of severe allergic reactions.

FDA Authorization Status

As of January 26, 2023, Evusheld is not authorized for emergency use in the United States. The FDA determined that the treatment is unlikely to protect against the SARS-CoV-2 variants that are currently most common. Because the virus changes over time, the antibodies in Evusheld may no longer be able to neutralize the circulating strains effectively.

Usage and Limitations

Not a treatment: Evusheld is intended for pre-exposure prophylaxis (prevention) and is not authorized to treat individuals who already have COVID-19.
Not a vaccine substitute: It is not a replacement for vaccination in people for whom COVID-19 vaccination is recommended.
Eligibility: When authorized, it was restricted to adults and pediatric patients (12 years of age and older weighing at least 40 kg) with specific medical conditions or treatments that suppress the immune system.

Evusheld

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

Found an Error?

Find Discounts for Evusheld

Hospitals.net Disclosure